Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance

Materia Medica

Status and phase

Completed

Phase 3

Conditions

Impaired Glucose Tolerance

Treatments

Drug: Subetta

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03725033

MMH-SU-006

Details and patient eligibility

About

Purpose of the study:

to assess the efficacy of Subetta in the treatment of impaired glucose tolerance
to assess the safety of Subetta in the treatment of impaired glucose tolerance.

Full description

Design: a multicenter, double-blind, placebo-controlled, parallel-group randomized trial.

The study will enroll outpatients adults aged 18 to 70 years with impaired glucose tolerance (IGT) who did not receive glucose-lowering agents previously. Persons with pre-diabetes, obesity (especially with visceral or abdominal obesity), dyslipidemia (with high triglycerides and/or low-density lipoproteins), hypertension, diabetes in first-degree relatives will be considered as potential candidates to participate in the study.

After the patient's information sheet and the form of informed consent for participation in the study are signed on the screening (visit 0; day from -7 to 0), complaints and history are collected, registration of concomitant conditions and diseases, objective examination, calculation of body mass index (BMI), oral glucose tolerance test (OGTT), fasting blood glucose. Furthermore, blood samples (for testing HbA1c, chemistry and hematology, HLA genotyping) and urine sample will be collected; concomitant therapy will be recorded, diet and physical activity recommendations will be given. All women of childbearing potential will be administered pregnancy tests.

If eligibility criteria are met and there are no non-inclusion criteria on Visit 1 (Day 1), the patient is randomized to one of two groups: the Subetta group (patients will take 2 tablets twice a day for 12 weeks) or placebo group (patients will take a placebo according to the scheme of Subetta for 12 weeks).

In the course of the study, two more visits in 4 (Visit 2) and 12 (Visit 3) weeks are planned, during these weeks complaints are recorded, a patient's examination is recorded, therapy compliance and safety are assessed. On Visit 3 OGTT, fasting blood glucose, blood samples (for HbA1c, chemistry and hematology) and urinalysis will be performed.

The duration of observation period shall be up to 13 weeks. During the study the treatment for underlying conditions will be allowed with the exception of the drugs indicated in the section "Prohibited concomitant therapy".

Enrollment

538 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Outpatients aged 18 to 70 years.
Impaired glucose tolerance (plasma glucose from 7.8 to 11.0 mmol / L 2 hours after a 75 g oral glucose consumption during an oral glucose tolerance test, while fasting plasma glucose <7.0 mmol / L).
HbA1c is 5.7-6.4%.
The body mass index is 25.0-39.9 kg / m^2.
Consent to use reliable contraceptive methods during the study (for men and women with reproductive potential).
The presence of the signed informed consent form to participate in the clinical trial.

Exclusion criteria

Type 1 or type 2 diabetes.
Use of any medications indicated in the section "Prohibited concomitant medications".
Acute or exacerbation / decompensation of a chronic disease of any etiology at the time of the examination or during the previous week.
Uncontrolled arterial hypertension with blood pressure: systolic blood pressure > 160 mm Hg and/or diastolic blood pressure > 110 mm Hg.
Acute coronary syndrome, myocardial infarction, acute impairment of cerebral circulation during the previous 6 months prior to enrollment.
Unstable or life-threatening arrhythmia during the previous 3 months prior to enrollment.
Acute and chronic heart failure with functional class III or IV (according to the classification of the New York Heart Association, 1964).
Respiratory failure.
Chronic kidney disease (classes C3-5 A3).
Hepatic insufficiency (class C according to Child-Pugh).
Presence or suspicion of oncology disease.
The presence of an allergy / hypersensitivity to any component of the medication administered during the treatment.
Alcohol consumption > 2 alcohol units for males and > 1 alcohol unit for females per day.
Mental illness or drug abuse in anamnesis.
Bariatric surgery in anamnesis, any surgery for 3 months before enrollment.
Pregnancy, breast-feeding; childbirth less than 3 months before enrollment.
Participation in other clinical trials for 3 months before enrollment in this study.
Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).
Patients who work for MATERIA MEDICA HOLDING (i.e. the company's employees, temporary contract workers, appointed officials responsible for carrying out the research or immediate relatives of the aforementioned).